跳至主要内容
临床试验/CTRI/2021/04/033099
CTRI/2021/04/033099已完成3 期

A Prospective, Randomized, Open Label Study to Evaluate the Safety and Efficacy Of Mulmina Orange Amla Ready To Drink As A Supplement In Pregnant Woman at High Risk for Preeclampsia

Jagdale industries pvt Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Female volunteer aged more than 18 to 45 years
  • 2.If pregnant, should have completed 1st trimester of the pregnancy
  • 3.Pregnant Woman At High Risk For Preeclamsia
  • 4.Willing to give written consent to participate

排除标准

  • 1.Patients with preexisting severe systemic disease necessitating long term medication.
  • 2.Patients with known history of diabetes mellitus.
  • 3.Evidence of significant uncontrolled co morbid disease which in the investigators opinion would jeopardize patient participation.
  • 4.History of cancer including solid tumors hematologic malignancies and carcinoma in situ
  • 5.Any neurological congenital or acquired vascular or systemic disorder which could affect any of the efficacy assessments.
  • 6.Participation in the current or previous treatment with any approved or investigational health supplements during the past one month.

研究者

相似试验